Skip to content
Companies

Lyora Therapeutics

Clinical-stage biotechnology company dedicated to developing groundbreaking therapies specifically for chronic rhinosinusitis (CRS), a prevalent inflammatory condition affecting the nasal passages and sinuses

Raised to date

$525K

of $2M offered across 1 Form D filing

Still open
$1.5M
Investors
4
Last filed
Mar 11, 2025

About

By leveraging innovative technologies, Lyra aims to provide effective solutions for CRS patients who often endure ineffective treatments and potentially invasive surgeries.

Lyra stands out through its proprietary XTreo technology platform, which enables sustained, localized medication delivery to ENT tissues without the need for invasive procedures.

Funding

  • Option to acquireFiled Mar 11, 2025Form D
    $525K/ $2M

Product

LYR-210

Therapeutic Implant

LYR-210 is a bioresorbable nasal implant specifically designed to deliver continuous anti-inflammatory medication for up to six months directly to the sinonasal passages. This innovative solution targets chronic rhinosinusitis patients who have not yet undergone sinus surgery, aiming to alleviate their symptoms effectively without requiring invasive interventions.

  • Bioresorbable implant
  • Delivers medication for up to 6 months
  • Non-invasive application

Built for

Adult CRS patients

People on file